Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Ascelia Pharma AB (7ZA.F) Follow Add holdings 0.2075 -0.0560 (-21.25%) At close: April 25 at 8:06:40 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 7ZA.F 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 7ZA.F View More All News Press Releases SEC Filings Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1 Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion Ascelia Pharma Announces Publication of Orviglance Study in Investigative Radiology Notice of Annual General Meeting in Ascelia Pharma AB Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025 Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025 Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025 Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB Ascelia Pharma AB (FRA:7ZA) (Q4 2024) Earnings Call Highlights: Strategic Advances and ... Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study